AXL expression is associated with multiple processes in cancer progression, including invasive tumor growth, therapy resistance, a more migratory mesenchymal phenotype, and poor clinical outcomes (9–11), and is also expressed on tumor-associated immune and endothelial cells. The gene discussed is AXL; the disease is neoplasm.